Paroxetine decreases platelet serotonin storage and platelet function in human beings

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 4, 2000, Pages 435-442

  Hergovich, Nicole ^a   Aigner, Martin ^a   Eichler, Hans Georg ^a   Entlicher, Jesusa ^a   Drucker, Christa ^a   Jilma, Bernd ^a,b  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD63 ANTIGEN; PAROXETINE; SEROTONIN; THROMBIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; ARTERY DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SEROTONIN RELEASE; SHEAR STRESS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ADULT; BLOOD PLATELETS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; MALE; P-SELECTIN; PAROXETINE; PROTHROMBIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; VON WILLEBRAND FACTOR;

EID: 0033736177     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.110456     Document Type: Article

References (36)

1. Pathophysiological relevance of serotonin
2. Local effect of serotonin released during coronary angioplasty
3. Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo: Thromboxane A2 and serotonin are possible mediators
4. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors
5. An overview of hemostasis
6. Ca2+ as messenger of 5HT2-receptor stimulation in human blood platelets
7. Potent depletion of 5HT from monkey whole blood by a new 5HT uptake inhibitor, paroxetine (FG 7051)
8. Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors
9. Seasonal variation in platelet [3H]paroxetine binding in healthy volunteers: Relationship to climatic variables
10. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100
11. Serotoninergic status in patients with hereditary vascular retinopathy syndrome
12. Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin-induced thrombocytopenia
13. Therapeutic monitoring of von Willebrand disease: Interest and limits of a platelet function analyser at high shear rates
14. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system
15. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion
16. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers
17. Can the platelet function analyzer PFA-100 test substitute for the template bleeding time in routine clinical practice?
18. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis
19. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: Effects of clomipramine and fluoxetine
20. Platelet storage pool deficiency: Diagnosis in patients with prolonged bleeding times and normal platelet aggregation
21. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: Studies on one hundred six patients
22. Differential induction of P-selectin expression on platelets by two cell separators during plateletpheresis and the effect of gender on the release of soluble P-selectin
23. Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans
24. Flow cytometric analysis of reticulated platelets: Evidence for a large proportion of non-specific labelling of dense granules by fluorescent dyes
25. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans
26. Safety issues of plateletpheresis: Comparison of the effects of two cell separators on the activation of coagulation, fibrinolysis, and neutrophils and on the formation of neutrophil-platelet aggregates
27. Regulation of adhesion molecules during human endotoxemia: No acute effects of aspirin
28. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients
29. Amplification mechanisms in platelet activation and arterial thrombosis
30. Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT 1D beta receptors
31. The role of serotonin in thrombogenesis
32. Platelet amplification of vasospasm
33. Potential usefulness of combined thromboxane A2 and serotonin receptor blockade for preventing the conversion from chronic to acute coronary artery disease syndromes
34. Bruising associated with the use of fluoxetine
35. Fluoxetine and the bleeding time
36. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease